Phase 2 Study of HKI-272 in Subjects With Advanced Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Neratinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Puma Biotechnology
- 10 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated
- 21 Oct 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017 as reported by ClinicalTrials.gov record.